Payment overview · 2025
General Payments
$772.01
47 reported records · 13 companies
Healthcare provider profile · identity verified
Jonathan E Alley, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ANGOLA, IN · NPI 1083672919
Verified facts
What the public records show
CMS Open Payments records show Jonathan E Alley, D.O. received $772.01 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SEROQUEL as an associated drug or biological on 59 records involving 53 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Seroquel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $210.91 | 27.3% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $145.06 | 18.8% | 13 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $139.14 | 18.0% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.77 | 7.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.17 | 7.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.44 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.80 | 4.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.44 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.24 | 2.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $15.79 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.87 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.78 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.60 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $772.01 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $180.84 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $145.06 | 13 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $139.14 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.37 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $74.55 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.17 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 136 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SEROQUEL open payments reported associated product |
CMS Open Payments — General Payments 59 supporting records · 53 recipient NPIs · example record 1241586771 |
Seroquel · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
136 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
228 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 863 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 760 | 106 |
| Omeprazole | Omeprazole | 554 | 83 |
| Lisinopril | Lisinopril | 544 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 71 |
| Furosemide | Furosemide | 398 | 69 |
| Gabapentin | Gabapentin | 392 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 51 |
| Metformin Hcl | Metformin Hcl | 349 | 70 |
| Celecoxib | Celecoxib | 315 | 56 |
| Carvedilol | Carvedilol | 281 | 39 |
| Trazodone Hcl | Trazodone Hcl | 271 | 42 |
| Donepezil Hcl | Donepezil Hcl | 269 | 24 |
| Tramadol Hcl | Tramadol Hcl | 258 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 249 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 37 |
| Losartan Potassium | Losartan Potassium | 240 | 42 |
| Famotidine | Famotidine | 235 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 51 |
| Eliquis | Apixaban | 228 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 222 | 37 |
| Irbesartan | Irbesartan | 207 | 34 |
| Baclofen | Baclofen | 188 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 36 |
| Meloxicam | Meloxicam | 178 | 40 |
| Simvastatin | Simvastatin | 165 | 36 |
| Alprazolam | Alprazolam | 159 | 23 |
| Potassium Chloride | Potassium Chloride | 158 | 20 |
| Lorazepam | Lorazepam | 152 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 20 |
| Sertraline Hcl | Sertraline Hcl | 140 | 23 |
| Pregabalin | Pregabalin | 138 | 20 |
| Mounjaro | Tirzepatide | 136 | 20 |
| Cefuroxime | Cefuroxime Axetil | 130 | 89 |
| Ozempic | Semaglutide | 125 | 25 |
| Buspirone Hcl | Buspirone Hcl | 124 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 123 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 37 |
| Montelukast Sodium | Montelukast Sodium | 114 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 21 |
| Xarelto | Rivaroxaban | 111 | 12 |
| Aripiprazole | Aripiprazole | 109 | 23 |
| Finasteride | Finasteride | 109 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 20 |
| Allopurinol | Allopurinol | 101 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 15 |
| Levofloxacin | Levofloxacin | 91 | 57 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 24 |
| Ezetimibe | Ezetimibe | 87 | suppressed |
| Naproxen | Naproxen | 83 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 52 |
| Azithromycin | Azithromycin | 82 | 60 |
| Prednisone | Prednisone | 82 | 42 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 16 |
| Levetiracetam | Levetiracetam | 81 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 72 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | suppressed |
| Topiramate | Topiramate | 65 | suppressed |
| Bumetanide | Bumetanide | 64 | suppressed |
| Loperamide | Loperamide Hcl | 64 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 17 |
| Mirtazapine | Mirtazapine | 62 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | 16 |
| Atenolol | Atenolol | 60 | suppressed |
| Ondansetron Odt | Ondansetron | 60 | 25 |
| Nifedipine Er | Nifedipine | 57 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 14 |
| Cilostazol | Cilostazol | 55 | suppressed |
| Estradiol | Estradiol | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Chlorthalidone | Chlorthalidone | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 13 |
| Torsemide | Torsemide | 51 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 21 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 44 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Kerendia | Finerenone | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 13 |
| Calcitriol | Calcitriol | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 12 |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 23 |
| Cholestyramine | Cholestyramine (With Sugar) | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 11 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 12 |
| Temazepam | Temazepam | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 11 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 27 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Cefadroxil | Cefadroxil | 25 | 21 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Acetic Acid | Acetic Acid | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 13 |
| Etodolac | Etodolac | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Fluorometholone | Fluorometholone | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Quviviq | Daridorexant Hcl | 14 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Seroquel | Quetiapine Fumarate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $772.01 · 47 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COLLAGENASE SANTYL, Cologuard Collection Kit, EVKEEZA, FARXIGA, MOUNJARO, PREVNAR 20, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error